Need Help? Contact Us.

Enquire now

LISA-TRACKER Duo Golimumab

Product Description

LISA-TRACKER Duo Golimumab is an enzyme linked immunoassay (ELISA) for the quantitative determination of Golimumab (anti-TNFα) and anti-Golimumab antibodies in human serum samples.

  • Comprehensive menu in inflammatory diseases and oncology
  • Validated on principle drug and biosimilars
  • Ready to use reagents
  • Standardised protocols from sample collection to result interpretation
  • Automation ready – protocols available on several open platform ELISA systems
    1. Arends S et al. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2010 Sep-Oct;28(5):661-8.
    2. Bendtzen K. Is There a Need for Immunopharmacologic Guidance of Anti–Tumor Necrosis Factor Therapies. ARTHRITIS & RHEUMATISM Vol. 63, No. 4, April 2011, pp 867–870.
    3. Desroches M et al. Treatment failure with antagonists of TNF-α: mechanisms and implications for the care of patients. Eur. Cytokine Netw., Vol. 21 n° 4, December 2010, 226-31.
    4. Edrees AF et al. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol. 2005 Jul-Aug;23(4):469-74.
    5. Koren E et al. Recommendation on risk-based strategies for detection and characterization of antibodies against biotechnology products. Journal of Immunological Methods, 333 (2008) 1-9.
    6. Mire-Sluis AR et al. Recommendation for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. Journal of Immunological Methods, 289 (2004) 1-16.
    7. Ram Raj Singh, & al. TNFα blockade in human diseases: mechanisms and future. Clin.Immunol., 2008 February; 126(2):121-136.

Add to Enquiry Basket

LISA-TRACKER Duo Golimumab

Quantity

Related Products

Assays Certification Platform Clinical Area Portfolio RUO/IVD
LISA-TRACKER Golimumab CE Marked Therapeutic Drug Monitoring TDM IVD
LISA-TRACKER anti-Golimumab CE Marked Therapeutic Drug Monitoring TDM IVD
LISA-TRACKER Duo Adalimumab CE Marked Therapeutic Drug Monitoring TDM IVD
LISA-TRACKER Duo Infliximab CE Marked Therapeutic Drug Monitoring TDM IVD
LISA-TRACKER Duo Certolizumab CE Marked Therapeutic Drug Monitoring TDM IVD
LISA-TRACKER Duo Etanercept CE Marked Therapeutic Drug Monitoring TDM IVD
LISA-TRACKER Duo Rituximab CE Marked Therapeutic Drug Monitoring TDM IVD
LISA-TRACKER Duo Secukinumab CE Marked Therapeutic Drug Monitoring TDM IVD
LISA-TRACKER Duo Ustekinumab CE Marked Therapeutic Drug Monitoring TDM IVD
LISA-TRACKER Duo Vedolizumab CE Marked Therapeutic Drug Monitoring TDM IVD
LISA-TRACKER Duo Tocilizumab CE Marked Therapeutic Drug Monitoring TDM IVD
This site is registered on wpml.org as a development site.